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ABSTRACT
Aortic valve repair is still emerging, and its role in the
treatment of bicuspid aortic valve disease (BAVD) is
not yet fully understood. Our objective is to synthesise
available evidence on outcomes after surgical aortic
valve repair in patients with BAVD. We conducted a
systematic review of clinical studies using prespecified
methods for searching, identifying and selecting
eligible studies in 4 databases, and synthesising results
(PROSPERO 2014:CRD42014014415). 2 researchers
independently reviewed full-text articles and extracted
data. The results of included studies were quantitatively
synthesised in frequentist meta-analyses. We included
11 aortic valve repair studies or study arms with a total
of 2010 participants. Pooled estimates for the
proportion of patients surviving at 30 days, 1 year,
5 years and 10 years were 0.995 (95% CI 0.991 to
0.995), 0.994 (0.989 to 0.999), 0.945 (0.898 to 0.993)
and 0.912 (0.845 to 0.979), respectively. The pooled
proportion of late deaths from valve-related causes was
0.008 (0.000 to 0.019) at a mean follow-up of
3.5 years. Proportion of patients with valve-related
reinterventions was 0.075 (0.037 to 0.113) at a mean
follow-up of 3.9 years, and the linearised reintervention
rate was 1.3 (0.7 to 1.9) per 100 patient-years.
Outcome reporting was insufficient to pool the results
for a number of predefined outcomes. In conclusion,
existing evidence on aortic valve repair in BAVD is
limited to mostly small case series, case–control and
small retrospective cohort studies. Despite the low
quality, available evidence suggests favourable survival
outcomes after aortic valve repair in selected patients
with BAVD. Valve-related reinterventions at follow-up
are common in all patients undergoing repair surgery.
INTRODUCTION
Bicuspid aortic valve disease (BAVD) is the
most common congenital heart disease,
affecting 1–2% of the population.1
Complications associated with BAVD include
aortic stenosis, regurgitation, infective endo-
carditis and aortic dissection.2 Depending on
the manifestation of BAVD, different treat-
ment options exist. The most common treat-
ment, surgical replacement of the
dysfunctional native valve, has some
limitations. Replacement with a mechanical
prosthesis requires lifelong anticoagulation
medication, potentially constraining the
patient’s lifestyle. In addition, the choice of
the valve size is challenging when patients
are still growing. Biological prostheses have
not yet proven to be a durable alternative,
particularly in younger patients. The Ross
procedure is associated not only with subse-
quent dilation of the aortic annulus but also
with an increased risk for aortic insufﬁciency
and pulmonary homograft insufﬁciency.3
In patients with suitable morphology of the
diseased valve (typically only patients with
aortic regurgitation), repair of the aortic
valve is a desirable option. The development
of aortic valve repair as an alternative to
replacement has been driven by potential
beneﬁts of preserving the native valve, which
include avoiding anticoagulation medications
and fewer complications of the operated
valve.4 5 However, evidence published to date
has been limited to relatively small case
series. Previous systematic reviews on valve
repair provided little information on the efﬁ-
cacy and safety of this intervention in
patients with BAVD.6 7 In recent years,
several world-leading centres have published
their growing experience with aortic valve
repair with large sample sizes. Including this
newly available information, our aim in this
study was to synthesise all available evidence
on immediate and long-term outcomes after
aortic valve repair in patients with BAVD.
METHODS
At the outset, we developed and made publi-
cally available a review protocol with prespe-
ciﬁed inclusion and exclusion criteria,
relevant outcomes and strategy for statistical
analysis on the PROSPERO website of the
University of York Centre for Reviews and
Dissemination (PROSPERO 2014:
CRD42014014415; http://bit.ly/20q683G).
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Our primary objective was to systematically collect and
synthesise available evidence on the effectiveness of
aortic valve repair. The protocol contained search strat-
egies for aortic valve repair and replacement studies to
allow quantitative assessment of the comparative effect-
iveness of the two interventions. We found that patients
undergoing the two interventions were not comparable,
particularly with respect to valve pathology (stenosis vs
regurgitation), and therefore we only report the ﬁndings
of aortic valve repair studies. Table 1 shows the main
parameters of this systematic review.
Literature search strategy
We searched online databases MEDLINE (via PubMed;
January 1990–October 2014), CINAHL Plus ( January
1990–October 2014), EMBASE ( January 1990–October
2014) and the Cochrane Library ( January 1990–
October 2014) using prespeciﬁed search terms and
phrases (search terms available in the online
supplementary material). Database searches were sup-
plemented by the reference lists obtained from three
review articles and one clinical practice guideline.6–9 We
conducted ﬁnal database searches on 30 October 2014.
Eligibility criteria
According to our prespeciﬁed inclusion criteria, studies
or study arms were eligible for inclusion if they had at
least 50 patients undergoing bicuspid aortic valve (BAV)
repair; were written in English language and were pub-
lished in peer-reviewed journals since 1990. Preliminary
searches had revealed a paucity of controlled studies,
and we therefore did not restrict inclusion to speciﬁc
study designs. We included studies reporting on patients
with BAVD undergoing any form of surgical aortic valve
repair, including valve-sparing replacement of the
ascending aorta (Yacoub and David procedures). While
valve-sparing procedures on the aortic root do not
necessarily include reconstruction of the aortic valve,
these procedures are often performed concurrently and
are aimed at preserving the native valve.
We excluded single case reports, conference abstracts,
review articles, references that reported none of the pre-
speciﬁed outcomes and animal studies.
Studies were screened at the abstract and study title
level by one researcher (MS). Full texts for articles
deemed eligible at this level were retrieved, and refer-
ences describing the same study were matched and
duplicates removed.
Full-text articles were independently assessed for inclu-
sion eligibility by two researchers (MS and HN).
Deviating decisions on inclusion were resolved by discus-
sion and consensus between the two researchers.
Data extraction and critical appraisal
Two researchers (MS and SP) carefully re-examined the
included studies and independently extracted prespeci-
ﬁed data using a standardised spreadsheet. Selection of
outcomes was based on guidelines.10 Extracted out-
comes were categorised into mortality (30-day; 1-year,
5-year and 10-year and valve-related mortality); complica-
tions before discharge (reoperations and neurologic
events); complications at follow-up (operated valve endo-
carditis; and thrombosis, embolism or bleeding event)
and reinterventions at follow-up (table 1). From each
study, we extracted relevant baseline characteristics and
outcomes for all patients who underwent aortic valve
repair. Data were extracted as the number of patients
with any given outcome. For 1-year, 5-year and 10-year
survival, as well as 1-year, 5-year and 10-year
reintervention-free survival, we extracted Kaplan-Meier
estimates rather than the actual number of patients
surviving.
We did not formally assess the risk of bias in included
studies. Available instruments, such as the Cochrane risk
of bias tool,11 have been developed for controlled trials
or observational cohort studies. Studies included in this
review were primarily case series and typical items
included in available risk of bias tools and checklists are
therefore not applicable.
Statistical analysis
To assess between-study heterogeneity, we plotted key
patient baseline characteristics against results of key out-
comes. We visually explored whether baseline character-
istics (including mean patient age; proportion of
patients with concomitant ascending aortic procedure;
proportion of patients in NYHA class III or IV; propor-
tion of patients with aortic stenosis or regurgitation)
Table 1 PICOS table
PICOS
Patient
population
▸ Patients with bicuspid aortic valve
disease above 1 month of age
Interventions ▸ Surgical valve repair
Comparators ▸ Any comparator
Outcomes Complications before discharge:
▸ Reoperation during index admission
▸ Neurologic event
Mortality:
▸ 30-day survival
▸ Survival at 1, 5 and 10 years follow-up
▸ Valve-related late mortality at
follow-up
Complications at follow-up:
▸ Operated valve endocarditis
▸ Thrombosis, embolism and bleeding
Reinterventions at follow-up:
▸ Reinterventions on operated valve at
follow-up
▸ Freedom from reintervention at 1, 5
and 10 years follow-up
Study designs ▸ Any study design
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were systematically correlated with favourable or
unfavourable results. Statistical heterogeneity of study
results was quantitatively assessed using the I2 statis-
tic.12 13 Results of individual studies were pooled using a
ﬁxed-effect model when between-study heterogeneity
was low (I2<25%), and a random-effects model when
between-study heterogeneity was moderate to high
(I2≥25%). In cases where a study had an event propor-
tion of 0 or 1, we imputed the average of the variances
of the other studies to obtain an estimate of the
variance.14
Pooled results are reported as proportions and 95%
CIs. Outcomes at follow-up are also presented as
number of events per 100 patient-years of follow-up with
corresponding 95% CIs. The linearised event rate for
each study was calculated as (events/(sample size×mean
follow-up time))×100.
Meta-analyses for all outcomes were carried out using
the ‘metan’ command in STATA, V.13 (College Station,
Texas, USA).
RESULTS
Through database searches and reference lists of key
reviews and clinical practice guidelines, we identiﬁed
1435 references. After eliminating duplicates, 1198
Figure 1 PRISMA flow chart.
Table 2 Patient baseline characteristics
Characteristic
Studies reporting
variable
(participants)
Patients overall (n) 2010
Mean age (years) 45.3 11 (2010)
Sex
Male (%) 82.1% 10 (1956)
Female (%) 17.9% 10 (1956)
Aortic valve pathology
Aortic regurgitation (%) 81.9% 10 (1956)
Aortic stenosis (%) 12.0% 7 (1241)
Patients in NYHA class III
or IV (%)
13.7% 4 (967)
Diameter asc. aorta (mean
mm (SD))
43.9
(7.5)
4 (351)
Patients with aortic
aneurysm (%)
30.0% 4 (809)
Patients with acute aortic
dissection (%)
0.5% 4 (806)
Patients with connective
tissue disorder (%)
3.4% 4 (282)
Procedure
Isolated valve repair (%) 39.5% 6 (1020)
Concomitant asc. aorta
repair or replacement
(%)
57.1% 10 (1956)
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records were excluded at the title and abstract screening
stage. Of 155 references assessed at the full-text stage, 11
studies15–25 with 2010 patients were deemed eligible for
inclusion (ﬁgure 1). Details of included studies are pro-
vided in the online supplementary material.
Baseline demographics
Overall, patient baseline characteristics (table 2) showed
relatively little variation across included studies (ﬁgure 2).
The mean patient age ranged from 41 to 64 years, with an
overall patient mean age of 45.3 years across all included
studies. Within individual studies, however, age was more
varied, with one study including patients ranging from 3 to
86 years15 and others including patients between 20 and
68 years of age.20 21 The proportion of patients with aortic
regurgitation was between 70% and 100% in all studies
except for one.23 Stenotic valves were present in 12% of
patients overall. Of seven studies reporting data for this
patient characteristic, ﬁve did not include any patients
with stenotic valves.
At baseline, ∼30% of patients had aortic aneurysms.
This patient characteristic was reported in only four
studies, three of which had a prevalence of aortic aneur-
ysm below 30%.
There was some variation in the proportion of patients
undergoing concomitant ascending aortic procedures at
baseline. Several techniques were used for interventions
on the ascending aorta, including variants of annulo-
plasty, aortoplasty and valve-sparing root replacement
(remodelling and reimplantation).
We observed statistical heterogeneity between individual
studies for most outcomes. However, we did not detect a
systematic relationship between baseline patient character-
istics and key outcomes (30-day survival; valve-related
mortality; valve-related reinterventions) through visual
inspection. For example, as shown in ﬁgure 3, valve-related
late mortality (Panel A) and valve-related reintervention
rates (Panel B) did not systematically vary with the propor-
tion of patients with concomitant ascending aortic proce-
dures. In a similar fashion, no systematic association
Figure 2 Distribution of patient baseline characteristics among included studies. Each bubble represents one study, with bubble
size representing study sample size. (A) Distribution of mean age in years; (B) distribution of proportion of patients with
concomitant ascending aorta repair or replacement; (C) distribution of proportion of patients in NYHA class III/IV; (D) distribution
of patients with aortic regurgitation; (E) distribution of mean ascending aorta diameter in mm and (F) distribution of patients with
aortic aneurysm.
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emerged when we plotted other patient baseline
characteristics against these key outcomes (plots presented
in online supplementary material).
Pooled estimates of immediate and follow-up outcomes
Pooled estimates for all outcomes are shown in table 3.
Complications before discharge were not commonly
reported. Synthesising the results of four studies (976
patients), we obtained a pooled estimate for the propor-
tion of patients with neurologic events before discharge
of 0.007 (95% CI from 0.995 to 0.999 (see table 3);
I2=28.5%). Reoperations during the initial admission
were reported in ﬁve studies (422 patients), with a
pooled estimated proportion of 0.054 (95% CI 0.010 to
0.099; I2=75.2%).
Survival within 30 days of aortic valve repair was 0.995
(95% CI 0.991 to 0.999; I2=0.0%). Figure 4 shows the
Kaplan-Meier estimates of survival at 1, 5 and 10 years
from studies reporting these estimates along with pooled
survival estimates. Pooled estimates showed a decrease in
survival from 0.994 (95% CI 0.989 to 0.999; I2=0.0%) at
1 year and 0.945 (95% CI 0.898 to 0.993; I2=84.4%) at 5
years to 0.912 (95% CI 0.845 to 0.979; I2=77.0%) at
10 years. Survival at 10 years of follow-up was extracted
from only two studies with estimates of 87%17 and
94%,24 respectively.
There was less variation in the proportion of patients
with valve-related deaths at follow-up. We obtained a
pooled estimate of 0.008 (95% CI 0.000 to 0.019;
I2=0.0%) for this outcome from seven studies with mean
follow-up ranging from 2 to 5.1 years (mean 3.5 years).
Pooled linearised valve-related mortality was 0.2 per 100
patient-years (95% CI 0.0 to 0.4; I2=0.0%).
Proportion of patients with valve-related reinterven-
tions at follow-up ranged from 0.01 to 0.18 in individual
studies; the pooled estimate was 0.075 (95% CI 0.037 to
0.113; I2=91.6%; ﬁgure 5). The mean follow-up time in
ten studies reporting the outcome ranged from 2 to
9 years (mean 3.9 years). Pooled estimate for the line-
arised reintervention rate was 1.3 per 100 patient-years
(95% CI 0.7 to 1.9; I2=69.2%).
Freedom from reintervention as measured by
extracted Kaplan-Meier estimates decreased from a
pooled proportion of 0.952 (95% CI 0.938 to 0.967;
I2=0.0%) at 1 year and 0.934 (95% CI 0.874 to 0.993;
I2=94.1%) at 5 years to 0.800 (95% CI 0.760 to 0.839;
I2=68.8%) at 10 years follow-up. Only two studies con-
tributed to the pooled estimate of reintervention-free
survival at 1 year (Kaplan-Meier estimates: 96.8%16 and
95.0%24). Reintervention-free survival at 10 years was
also only reported in two studies (Kaplan-Meier esti-
mates: 82.0%15 and 78.0%24).
Figure 3 Effect of concomitant ascending aorta procedure on outcomes at follow-up. Each bubble represents one study, with
bubble size representing study sample size. Only studies with data for proportion of patients with valve-related deaths at follow-up
(A) and valve-related reinterventions at follow-up (B) and the proportion of patients with ascending aorta replacement or repair at
the time of valve repair are shown. (A) Results for the proportion of patients with valve-related late mortality. Studies are ranked
by ascending proportion of patients with concomitant ascending aorta procedure; (B) results for the proportion of patients with
valve-related reinterventions at follow-up. Studies are ranked by ascending proportion of patients with concomitant ascending
aorta procedure.
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At a study-level mean follow-up time of 3.3 years
(mean follow-up ranging from 2.0 to 5.1 years across
studies), endocarditis of the operated valve was observed
in an estimated 1.1% of patients (95% CI 0.002 to 0.020;
I2=0.0%). The pooled linearised rate for operated valve
endocarditis was 0.3 per 100 patient-years (95% CI 0.0
to 0.6; I2=0.0%). Other complications at follow-up, cap-
tured in the composite indicator for thrombosis, embol-
ism and bleeding, did not occur in the four studies
reporting these outcomes.
DISCUSSION
In this paper, we systematically assessed and synthesised
the available evidence on outcomes after aortic valve
repair in patients with BAVD. In this comprehensive
assessment, which included all techniques preserving
the native valve, we found 11 studies matching our
inclusion criteria. The evidence base consisted of
single-centre case series with mean patient age at the
study-level between 41 and 64 years, some of which retro-
spectively compared results between different types of
valve repair. Pooled estimates from our meta-analyses
suggest favourable 30-day and long-term survival after
BAV repair. Although the durability of aortic valve repair
in this patient population remains uncertain, our
meta-analysis suggests that this intervention can contrib-
ute to a positive outlook for patients diagnosed with
BAVD, who, as observed in a population-based study in
Minnesota, can expect similar 25-year survival as the
general population once the diagnosis is made.26 Aortic
valve-preserving surgery is still undergoing changes as a
surgical technique, and its use is limited to centres of
excellence with experienced surgeons.27 The favourable
ﬁndings of our systematic review should be interpreted
against this background.
Anatomic features of the individual patient’s aorta (in
particular dilated aortic root) and conﬁguration of the
diseased valve are important considerations when choos-
ing the type of valve repair. At the study level, we did not
detect a systematic association between concomitant
ascending aorta procedures and key outcomes. Two of
the included studies did not ﬁnd a statistically signiﬁcant
difference in survival at follow-up between patients
undergoing isolated valve repair and patients with con-
comitant aortic root replacement or sinotubular junc-
tion remodelling.15 25 Other studies found a positive
effect from aortic root replacement or remodelling of
the sinotubular junction at the time of aortic valve
repair;15 16 18 this ﬁnding has led to increased advocacy
for aggressive root replacement even in patients with
mild or moderate root dilation.18
Table 3 Pooled results
Outcome
Pooled estimate
(95% CI)
Number of studies reporting
outcome (participants)
Complications before discharge
Reoperation during index admission, proportion 0.054 (0.010 to 0.099)* 5 (422),16–19 25
Neurologic event, proportion 0.007 (0.000 to 0.018)* 4 (976)16 18 24 25
Mortality
30-day survival, proportion 0.995 (0.991 to 0.999) 9 (1844)15–20 23–25
Survival at 1 year, proportion 0.994 (0.989 to 0.999) 5 (1038)16 17 20 24 25
Survival at 5 years, proportion 0.945 (0.898 to 0.993)* 4 (1009)17 23–25
Survival at 10 years, proportion 0.912 (0.845 to 0.979)* 2 (836)17 24
Valve-related late mortality at follow-up
Proportion 0.008 (0.000 to 0.019) 7 (584)16–20 23 25
Per 100 patient-years 0.2 (0.0 to 0.4) 7 (584)16–20 23 25
Complications at follow-up
Operated valve endocarditis
Proportion 0.011 (0.002 to 0.020) 8 (615)16 18–23 25
Per 100 patient-years 0.3 (0.0 to 0.6) 8 (615)16 18–23 25
Thrombosis, embolism, and bleeding
Proportion 0† 4 (304)16 20 23 25
Per 100 patient-years 0† 4 (304)16 20 23 25
Reinterventions at follow-up
Reinterventions on operated valve at follow-up
Proportion 0.075 (0.037 to 0.113)* 10 (1944)15–18 20–25
Per 100 patient-years 1.3 (0.7 to 1.9)* 9 (1385)16–18 20–25
Freedom from reintervention at 1 year 0.952 (0.938 to 0.967) 2 (799)16 24
Freedom from reintervention at 5 years 0.934 (0.874 to 0.993)* 5 (1026)16 22–25
Freedom from reintervention at 10 years 0.800 (0.760 to 0.839)* 2 (1287)15 24
The table shows the number of studies reporting each outcome and the corresponding number of participants in these studies.
*Weights from random effects analysis. Results without indicator are from fixed-effect analysis with inverse variance weighting.
†No CIs computed because of 0 variance in all four studies reporting the outcome.
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Our pooled estimate of 30-day survival after aortic
valve repair was 0.995 (95% CI 0.991 to 0.999). This sug-
gests a considerably lower early mortality rate compared
to a previous meta-analysis which did not focus exclu-
sively on patients with BAVD (pooled estimated early
mortality 0.026, 95% CI 0.014 to 0.044),6 potentially
highlighting differences and the need for differentia-
tions of patients with bicuspid versus tricuspid valves.
However, two studies found no difference in long-term
survival between the two valve types,20 22 although this
might have been due to the rare occurrence of late
deaths after the procedure. Our results conﬁrm and
extend the ﬁndings of another systematic review of 30,
often small, aortic valve repair studies in BAVD patients
which found a median 30-day mortality rate of 0%.7
Reinterventions at follow-up are not uncommon after
BAV repair. Pooled estimates for freedom from
valve-related reinterventions at follow-up showed a
decline from 93.4% at 5 years to 80.0% at 10 years. This
suggests increased failure of valve repair after 10 years.
In the two studies reporting reintervention-free survival
at 10 years, reoperation was performed mainly for recur-
rent regurgitation15 and cusp prolapse.24
Whether replacement of the valve is a more durable
alternative remains elusive. Some series of aortic valve
replacement in BAVD patients report proportions of
patients with reinterventions well below 5%28 29 while
others report considerably higher rates.30 31 However, a
direct comparison of outcomes after valve repair and
replacement may not be feasible. Repair techniques are
not practical for all aortic valve pathologies. We found
that most series excluded patients with aortic valve sten-
osis from aortic valve repair. In addition, expected bene-
ﬁts from preserving the native valve may play a more
prominent role in treatment decisions for younger and
healthier patients. The absence of lifelong need for
anticoagulation medication may be a stronger argument
for young patients who want to maintain an active life-
style. Such differences in the patient groups undergoing
aortic valve repair or replacement can systematically
inﬂuence the results of published case series. Indeed,
authors of included studies mentioned that only selected
patients underwent repair.17 18 22 We included only
studies with 50 or more participants to obtain more
robust results about the effectiveness of aortic valve
repair compared to very small case series. In our sample
of 11 studies, none was conducted exclusively in young
patients. The low number of patients <30 years seen at
any particular centre may prohibit the publication of
large patient series focusing on this young patient
group. This hints at a gap in knowledge about outcomes
after aortic valve repair in the group which is most likely
to beneﬁt from it, young adults.
Comparison of surgical aortic valve repair and replace-
ment is only feasible for similar patient groups in the
setting of a controlled clinical trial. Our database search
retrieved only one such study with sufﬁciently large
sample size which found no statistically signiﬁcant differ-
ence in 10-year survival and freedom from reoperation
between aortic valve repair and replacement.17
Compared to another systematic review published in
2013,7 our study shows less variation and slightly better
results reported by individual centres. Different inclu-
sion criteria and a gap in time between the execution of
the two reviews can serve as possible explanation for dif-
ferences in ﬁndings. First, we excluded very small
studies. Included studies were conducted at larger
centres with more experienced surgeons, which is likely
to positively impact on desirable outcomes. Second,
know-how in surgical repair of bicuspid aortic valves is
still evolving, suggesting favourable results in more
recently operated patients. In one study comparing the
risk of patients for undergoing aortic valve replacement
at follow-up between patients who had their initial aortic
valve repair before and after 2000, a trend towards
better outcomes after 2000 was discovered, suggesting a
learning curve effect for operating surgeons.17 In
Figure 4 Survival at follow-up. Kaplan-Meier estimates from
included studies for survival at 1, 5 and 10 years follow-up.
Each bubble represents one study, with bubble size
representing study sample size. Pooled estimates of survival
are shown as empty circles.
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addition, it is possible that centres are improving with
respect to appropriate patient identiﬁcation and selec-
tion for aortic valve repair. Michelena et al32 identiﬁed
gaps in the knowledge about BAVD and maintain that
research into this complex disease has ‘generated more
questions than answers’.
Limitations
Our study has several limitations. First, data on speciﬁc
outcomes were not always available from all included
studies, leading to a small evidence base for some out-
comes. Second, included studies are mostly case series
or retrospective observational studies, which rank the
overall evidence between levels 3 and 4.33 Bias is more
likely to occur in methodologically less rigorous study
designs and systematic reviews including such study
designs are prone to bias themselves.34 Selection of
healthier patients for surgical methods that are still in
development can bias results towards more beneﬁcial
outcomes. Third, despite our best efforts to account for
differences in patient baseline characteristics, unmeas-
ured traits could have confounded the results. For
example, fusion of the right and left coronary cusps is
associated with more aggressive progression of aortic
dilation.35 However, we were not able to assess whether
valve morphology impacted on patients outcomes, as
this characteristic was not commonly reported in
included studies. Finally, aortic valve repair is not a
homogenous surgical technique. To accommodate
characteristics of individual patients, a variety of
approaches is used, including replacement or repair of
the ascending aorta. The objective of this meta-analysis
was to synthesise available evidence on aortic-valve pre-
serving surgery in patients with BAVD, and we therefore
did not distinguish between speciﬁc surgical techniques.
The conclusions drawn from this analysis may therefore
not be generalisable for speciﬁc techniques.
CONCLUSIONS
Our systematic review demonstrated that the clinical lit-
erature on outcomes after aortic valve repair in BAVD
patients is still limited to mostly case series including in
some cases retrospective comparisons of repair techni-
ques within individual centres. Methodologically rigor-
ous controlled studies comparing outcomes after aortic
valve repair with alternatives, speciﬁcally aortic valve
replacement, are needed. Aortic valve repair is still
developing at individual centres, and its role in the treat-
ment of BAVD is not yet fully understood. While mainly
used in aortic valve insufﬁciency, additional centre-
speciﬁc applications for the treatment of stenotic bicus-
pid valves have been described. Synthesising the avail-
able evidence from case series, we found that aortic
valve repair in patients with BAVD appears to be asso-
ciated with favourable survival. No systematic inﬂuence
Figure 5 Proportion of patients
with valve-related reinterventions
at follow-up. Each bubble
represents one study, with bubble
size representing study sample
size. Pooled estimate of the
proportion is shown as empty
circle.
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of concomitant ascending aorta surgery at the time of
valve repair on patient outcome was shown in the
included studies. Questions remain regarding the dur-
ability of the procedure as valve-related reinterventions
at 10 years of follow-up are common in all patients
undergoing repair surgery.
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